Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

European Union — European Medicines Agency

Tracked across 78 events · 1186 articles · First seen Feb 10, 2025 · Last active Sep 23, 2026

Sentiment
5
Attention
7
Events
78
Relationships
22
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 -20
Regulatory
Impact: The European Union — European Medicines Agency's CHMP recommended the revocation of the marketing authorization for TAVNEOS, impacting its availability in the EU.
Jun 26, 2026 · 9 articles
4 20
Tech
Impact: The European Union — European Medicines Agency identified favipiravir as the most plausible candidate for hantavirus treatment under clinical trial or compassionate use protocols.
May 28, 2026 · 6 articles
4 50
Business
Impact: The European Union — European Medicines Agency conditionally approved Imlifidase and requested the PAES study, which has now been successfully completed, paving the way for a full marketing authorization application.
May 27, 2026 · 6 articles
4 -20
Regulatory
Impact: The European Union — European Medicines Agency, through its CHMP committee, issued the negative opinion that triggered the stock decline. Its decision is pivotal to Zevra's European market access for arimoclomol.
Jul 24, 2026 · 29 articles
4 0
Regulatory
Impact: The EMA is the regulatory body validating and assessing the application. Its decision will determine market access in Europe.
Aug 14, 2026 · 12 articles
6 0
Regulatory
Impact: The European Union — European Medicines Agency (EMA) is the overarching regulatory body whose CHMP adopted the positive opinion for DAYBU, facilitating its potential market entry in the EU.
Jun 26, 2026 · 6 articles
4 50
Tech
Impact: The European Union — European Medicines Agency granted PRIME designation for Privosegtor, another significant regulatory milestone that supports its development in Europe.
Jun 11, 2026 · 7 articles
4 0
Regulatory
Impact: The EMA initiated a phased review of daraxonrasib, accelerating the assessment process for a potential new pancreatic cancer therapy.
Jul 07, 2026 · 7 articles
4 5
Regulatory
Biopharmaceutical, a wholly-owned subsidiary of Biocon, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Union — European Medicines Agency issued a positive opinion recommending marketing authorisation for its Pertuzumab…
Impact: Its CHMP issued the positive opinion recommending marketing authorisation, advancing the application to the International — European Commission for final decision.
Sep 21, 2026 · 7 articles
4 0
Business
Impact: The European Union — European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of Dupixent for chronic spontaneous urticaria (CSU) in the European Union.
Feb 24, 2026 · 8 articles
6 50
Tech
Impact: The European Union — European Medicines Agency has released detailed guidance on computerized systems and data management, stressing the importance of secure, attributable and contemporaneous records, which accelerates the move toward automation.
Apr 07, 2026 · 8 articles
4 0
Regulatory
Impact: The European Union — European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on Omeros Corporation's drug narsoplimab, directly causing the company's stock price drop and triggering the subsequent investigation.
Jul 01, 2026 · 12 articles
4 10
Regulatory
Zealand Pharma announced on September 18, 2026 that the European Union — European Medicines Agency's European Union — Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending marketing authorization for Zeydovio…
Impact: Its CHMP committee issued the positive opinion that drives the event, reinforcing the agency's role as the gatekeeper for EU drug approvals.
Sep 18, 2026 · 6 articles
2 0
Regulatory
The International — European Commission approved AstraZeneca's Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate) as a maintenance treatment for asthma in patients aged 12 years and older whose disease is not adequately controlled by a medium-dose inhaled…
Impact: Its scientific assessment underpinned the approval, with the positive CHMP opinion paving the way for the International — European Commission decision.
Sep 23, 2026 · 10 articles
2 0
Regulatory
Roche announced on 10 September 2026 that the United States — Food and Drug Administration has granted Priority Review to a supplemental Biologics License Application for Enspryng (satralizumab) for the treatment of myelin oligodendrocyte glycoprotein…
Impact: The EMA validated Roche's application for Enspryng in MOGAD in Europe, advancing the parallel European regulatory pathway.
Sep 09, 2026 · 6 articles
4 0
Regulatory
Hundreds of patients in the United States have filed personal injury lawsuits against Novo Nordisk and Eli Lilly and Company, alleging that widely used GLP-1 medications including Ozempic, Wegovy, Mounjaro, Zepbound and Trulicity caused a…
Impact: Estimated NAION could affect up to one in 10,000 people with diabetes using GLP-1 medicines and required updated warnings on semaglutide product information in 2025. Its action sets a precedent that US regulators have not followed.
Sep 21, 2026 · 20 articles
4 0
Business
Impact: The European Union — European Medicines Agency>>> is involved in the approval process for Imlifidase>>>, with a payment contingent on its filing acceptance.
May 19, 2026 · 7 articles
1 5
Business
Boehringer Ingelheim announced the launch of PED Essentials, a free online e-learning hub designed to help patient organizations generate, analyze and share high-quality patient experience data (PED). The platform was co-created with patients and subject…
Impact: The EMA's September 2025 reflection paper on patient experience data is cited as the key regulatory backdrop making the launch timely, with final guidance expected soon.
Sep 17, 2026 · 6 articles
4 0
Tech
Impact: The European Union — European Medicines Agency has granted Lonvoguran ziclumeran Priority Medicines (PRIME) Designation, which supports the development of medicines that address unmet medical needs.
Jun 01, 2026 · 6 articles
6 30
Domestic
Impact: The European Union — European Medicines Agency recently recommended approval of Novo Nordisk's Semaglutide pill, which could pave the way for the first oral weight-loss drug in Europe, complementing France's reimbursement initiative.
May 28, 2026 · 6 articles
3 0
Regulatory
Impact: Immunome plans to submit a Marketing Authorization Application to the EMA by end of 2026, making the EMA a future regulatory body for varegacestat in Europe.
Jul 08, 2026 · 6 articles
3 5
Business
Impact: The EMA recommended expanding mRESVIA's license to all adults 18+, which may increase vaccine uptake.
Jul 09, 2026 · 6 articles
3 0
Regulatory
Impact: The EMA is also reviewing the combination for the same indication.
Jul 22, 2026 · 6 articles
2 50
Business
Impact: The EMA granted PRIME status to PentixaFor, providing enhanced support for its development and approval in European Union — Europe.
Jul 15, 2026 · 10 articles
4 0
Business
Impact: The EMA accepted the Marketing Authorisation Application for senaparib, a regulatory step that is critical for European Union — European market entry. Approval is expected in H2 2026.
Jul 31, 2026 · 8 articles
4 0
Regulatory
Impact: The EMA's advisory committee recommended approval, which preceded the International — European Commission's decision.
Aug 24, 2026 · 7 articles
4 0
Regulatory
Impact: The EMA validated the Marketing Authorization Application for AVT16 and AVT80, supporting European regulatory progress.
Aug 31, 2026 · 9 articles
2 0
Tech
Impact: The European Union — European Medicines Agency provides statistics on the prevalence of Dementia UK in Europe, underscoring the regional impact of the condition.
Jan 02, 2026 · 7 articles
6 0
Tech
Impact: The European Union — European Medicines Agency granted IBM System/4 Pi Orphan Drug designation, which can expedite its development and review process in Europe.
Jun 24, 2026 · 6 articles
4 0
Regulatory
Impact: The European Union — European Medicines Agency (EMA) is mentioned as a target for a Marketing Authorization Application (MAA) in 2026 for INmune Bio Inc.'s CORDStrom platform, indicating future regulatory efforts in the European Union.
Jun 25, 2026 · 6 articles
+ 48 more events View on Dashboard
GT Biopharma ↔ European Union — European Medicines Agency
GT Biopharma ↔ European Union — European Medicines Agency
Pfizer ↔ European Union — European Medicines Agency
Pfizer ↔ European Union — European Medicines Agency
United States — Food and Drug Administration ↔ European Union — European Medicines Agency
United States — Food and Drug Administration ↔ European Union — European Medicines Agency
International — European Commission ↔ European Union — European Medicines Agency
International — European Commission ↔ European Union — European Medicines Agency
Switzerland ↔ European Union — European Medicines Agency
Switzerland ↔ European Union — European Medicines Agency
Eli Lilly and Company ↔ European Union — European Medicines Agency
Eli Lilly and Company ↔ European Union — European Medicines Agency
European Union ↔ European Union — European Medicines Agency
European Union ↔ European Union — European Medicines Agency
United Kingdom ↔ European Union — European Medicines Agency
United Kingdom ↔ European Union — European Medicines Agency
United States ↔ European Union — European Medicines Agency
United States ↔ European Union — European Medicines Agency
Israel ↔ European Union — European Medicines Agency
Israel ↔ European Union — European Medicines Agency
ERGEN INTELLIGENCE
Track European Union — European Medicines Agency live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.